B2BROKER
4.4.2024 16:08:35 CEST | Business Wire | Press release
The latest major upgrade to B2Core was just released by B2Broker, significantly enhancing the platform's back-office and CRM solutions. The V2.1 upgrade delivers on the highly anticipated savings feature, introduces a new trading platform and PSP integrations, and drastically improves the user experience on the platform. Let’s explore:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240404452158/en/
B2Broker, a leading liquidity and technology provider, has just announced the release of a new version of B2Core, its sophisticated CRM and back-office solution. B2Core V2.1 integrates the TradeLocker trading platform inside its ecosystem, adds new PSPs and enhances the existing ones, and upgrades its UI. (Photo: Business Wire)
Polished UI & Peak Performance
Version 2.1 of B2Core brings a new user interface, major functionality improvements, and technical fixes.
- A Withdrawal summary provides comprehensive transfer information that features commissions, exchange rates and the net transaction amount.
- Account creation now enforces minimum deposit settings to maintain consistency in the back-office.
- On the Deposit, Withdraw, and Transfer pages, accounts in selectors are now categorised by type (e.g., Fiat, Coins, MT4, MT5) for easier navigation.
- Platform consistency is guaranteed by the Unified Date Format.
- The old and new UI settings can now be easily switched by users.
Integration with TradeLocker Trading Platform
B2Core introduces TradeLocker, an innovative trading platform seamlessly integrated into the trader's room. This addition enhances the company’s existing suite of integrated platforms, including MetaTrader 4, MetaTrader 5, cTrader and B2Trader, offering brokerages a complex set of trading solutions.
TradeLocker presents a comprehensive suite of powerful trading tools and instruments aiming to cater to a wide spectrum of clients, from novices to seasoned traders. The platform is equipped with versatile features designed to support a variety of trading strategies and preferences, facilitating a seamless and efficient trading experience for brokerage clients.
TradeLocker integrates with TradingView to offer a sophisticated charting capability, granting users access to an extensive array of customisable charts and indicators. The platform provides traders with modern tools to manage risks effectively.
Among its standout features are SL & TP Calculator, On-Chart Trading, One-click Trading, Trailing Stop Loss, and Social Mode, enabling traders to efficiently manage their trades engaging with the market. Users can easily develop or customise bots, signals, indicators, and strategies using the TradeLocker AI at TradeLocker Studio.
Payment Improvements and Integrations
Thanks to the V2.1 B2Core update, users now have more transaction options, and the scope of payment integrations has expanded.
Sqala supports deposits and withdrawals in Brazilian reals (BRL). It is renowned for its simplicity, competitive exchange rates, and a convenient dashboard that provides all the essential data. By including Sqala in its portfolio, B2Broker has increased the range of its solutions and fulfilled the needs of customers worldwide.
Transactions have been streamlined and fortified through several new improvements:
- Within the B2Core environment, BridgerPay provides a better deposit process through an automated data fill-in feature that streamlines transaction processing.
- Praxis configuration has been enhanced to improve transaction security. To comply with diverse regulatory standards, you can now enable clients from various countries to submit specific documents.
- The constructor payment adjustments allow clients to attach documents for deposits and withdrawals, ensuring maximum compliance and record accuracy.
The V2.1 upgrade has also brought back access to 1-2-Pay and WireCustom for deposits and withdrawals to expand the choices for transfers.
Engage Customers with Savings Feature
Last but not least, V2.1 adds a savings feature that lets users invest idle funds and get interest over specific periods. The savings programs currently support fixed savings, allowing users to receive fixed-interest rewards. Moreover, admins can access, modify, and initiate new savings programs with the presets page, effortlessly incorporating both business and client preferences.
The savings feature offers flexibility across the board, allowing users to set customised annual interest rates and adjust investment duration with 30-day intervals (30, 60, or 90 days). Brokers may also impose an early withdrawal penalty to maintain the viability of their savings plans.
The savings feature is highly customisable and configurable. The annual interest earnings option will motivate the clients to retain their funds within the broker’s ecosystem. Additionally, it enables brokers to increase fund retention and liquidity within B2Core, resulting in an advantageous situation for everybody involved.
Final Remarks
B2Core continues B2Broker’s mission to deliver quality across all products and services, ensuring maximum client satisfaction. The V2.1 update is another testament to raising industry standards!
The team is working on the complete transition of B2Core to the new interface. Additionally, B2Core intends to offer flexible interest rates for the savings plans. The team also works hard to add new integrations and expansions, allowing clients to enjoy a comprehensive CRM and back-office solutions suite!
Explore B2Core’s new features today and discover the benefits for your business.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240404452158/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom